ALDX:NSC-Aldeyra Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing Price

USD 8.65

Change

+0.18 (+2.06)%

Market Cap

USD 0.17B

Volume

0.04M

Yahoo Analyst Target

USD 19.80 (128.90%)

STA Analyst Target

USD 13.00 (50.29%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Aldeyra Therapeutics Inc is developing a treatment for diseases related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+1.89 (+1.07%)

USD 118.02B
GILD Gilead Sciences Inc.

+0.20 (+0.30%)

USD 88.20B
BIIB Biogen Inc.

+2.02 (+0.73%)

USD 59.02B
CELG Celgene Corporation

+1.92 (+2.57%)

USD 55.53B
SHPG Shire plc

+0.94 (+0.56%)

USD 51.75B
VRTX Vertex Pharmaceuticals Incorpo..

+0.06 (+0.04%)

USD 39.82B
REGN Regeneron Pharmaceuticals Inc.

-1.92 (-0.65%)

USD 31.78B
ALXN Alexion Pharmaceuticals Inc.

-0.36 (-0.30%)

USD 26.48B
BMRN BioMarin Pharmaceutical Inc.

-1.75 (-1.96%)

USD 15.48B
GRFS Grifols S.A.

-0.03 (-0.13%)

USD 15.39B

ETFs Containing ALDX

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.21% 74% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.21% 74% C 85% B
Trailing 12 Months  
Capital Gain 98.85% 80% B- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 98.85% 80% B- 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.95% 45% F 38% F
Dividend Return 1.95% 44% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.84% 69% D+ 36% F
Risk Adjusted Return 5.59% 45% F 29% F
Market Capitalization 0.07B 37% F 36% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -5.92 62% D- 76% C
Price/Book Ratio 4.30 47% F 27% F
Price / Cash Flow Ratio -1.74 60% D- 82% B-
Price/Free Cash Flow Ratio -6.81 60% D- 75% C
Management Effectiveness  
Return on Equity -70.82% 45% F 15% F
Return on Invested Capital -69.44% 45% F 13% F
Return on Assets -63.86% 33% F 10% F
Debt to Equity Ratio 4.00% 74% C 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

ALDX:NSC-Aldeyra Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing Price

USD 8.65

Change

+0.18 (+2.06)%

Market Cap

USD 0.17B

Volume

0.04M

Yahoo Analyst Target

USD 19.80 (128.90%)

STA Analyst Target

USD 13.00 (50.29%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-05-22